💛 A quick favor, if you've got a second.
We're really happy that you chose to read one of our stories and sincerely hope you'll stick around to read more. We took our paywall down — for now — but that won't last forever, and when the gate goes back up, we'd love for you to already be on the inside.
It's free. So please enter your email here and don't forget to like and follow us on all of your favorite Social Media platforms!
Researchers at Vanderbilt University have synthesized the first selective inhibitor of TAOK-1, a protein whose role in Alzheimer’s disease has remained largely unexplored until now. The breakthrough marks a significant step forward in understanding the molecular basis of the neurodegenerative disorder. The compound’s development provides scientists with a specialized tool to study this previously difficult-to-target protein.
In a parallel discovery, the research team also identified a second compound capable of activating all members of the TAOK protein family. This dual-compound approach offers researchers unprecedented flexibility in examining how different TAOK proteins influence disease progression. The activation compound represents an unexpected addition to the scientists’ arsenal of investigative tools.
Together, these two compounds could uncover previously hidden mechanisms driving Alzheimer’s disease development and degeneration. By selectively manipulating TAOK proteins in laboratory and animal models, researchers may identify new therapeutic targets. The findings could accelerate the search for effective treatment strategies addressing the disease’s underlying biological processes.
More Stories
Atlantic Hurricane Season Expected to Remain Quiet Through Mid-August Before Activity Picks Up
Millions of Homeowners Lack Flood Insurance Due to Confusion Over FEMA Risk Maps, Officials Warn
Research Points to Protein Buildup as Key Driver of Age-Related Neurological Disease